In the same context, venetoclax, an orally bioavailable Bcl-2-specific BH3 mimetic, has shown greater efficacy when combined with chemotherapies such as CHOP, R-CHOP, or bendamustine among others, in patients with relapsed or refractory non-Hodgkin's lymphoma [66, 68]. Here, BCL2 is linked to non-Hodgkin lymphoma.